These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 8815692

  • 1. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
    Freimuth WW.
    Adv Exp Med Biol; 1996; 394():279-89. PubMed ID: 8815692
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
    Demeter LM, Meehan PM, Morse G, Gerondelis P, Dexter A, Berrios L, Cox S, Freimuth W, Reichman RC.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb 01; 14(2):136-44. PubMed ID: 9052722
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
    Grodesky M, Acosta EP, Fujita N, Mason S, Gerber JG.
    HIV Clin Trials; 2001 Feb 01; 2(3):193-9. PubMed ID: 11590527
    [Abstract] [Full Text] [Related]

  • 7. Delavirdine: a review of its use in HIV infection.
    Scott LJ, Perry CM.
    Drugs; 2000 Dec 01; 60(6):1411-44. PubMed ID: 11152019
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C.
    J Virol; 2001 Jun 01; 75(11):4999-5008. PubMed ID: 11333879
    [Abstract] [Full Text] [Related]

  • 11. Delavirdine/protease inhibitor interactions.
    Gilden D.
    GMHC Treat Issues; 1996 Sep 01; 10(9):11-2. PubMed ID: 11363839
    [Abstract] [Full Text] [Related]

  • 12. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s.
    Fan N, Rank KB, Evans DB, Thomas RC, Tarpley WG, Sharma SK.
    FEBS Lett; 1995 Aug 14; 370(1-2):59-62. PubMed ID: 7544302
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [New combination medications].
    Agosto M.
    Sidahora; 1997 Aug 14; ():43-6. PubMed ID: 11364501
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antiviral roundup.
    Smart T, Torres G.
    GMHC Treat Issues; 1996 Aug 14; 10(8):6-7. PubMed ID: 11363720
    [Abstract] [Full Text] [Related]

  • 19. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
    Dueweke TJ, Pushkarskaya T, Poppe SM, Swaney SM, Zhao JQ, Chen IS, Stevenson M, Tarpley WG.
    Proc Natl Acad Sci U S A; 1993 May 15; 90(10):4713-7. PubMed ID: 7685109
    [Abstract] [Full Text] [Related]

  • 20. Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays.
    Gu Z, Quan Y, Li Z, Arts EJ, Wainberg MA.
    J Biol Chem; 1995 Dec 29; 270(52):31046-51. PubMed ID: 8537362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.